Evidence map›Paper›PMID 42094195›Full record

ArticleFrontiers in oncology2026

Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review.

Tian Tan, Xinhao Peng, Dan Shang, Linlin Zheng, Jie Chen, Hong Wu, Chenhui Cao, Senlin Xu, Chuan Xu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tian Tan *School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Xinhao Peng *Department of Oncology, Affiliated Hospital of Southwest Jiaotong University, The Third People's Hospital of Chengdu, Chengdu, Sichuan, China.
Dan Shang *Department of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Linlin ZhengDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Jie ChenDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Hong WuDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Chenhui CaoDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Senlin XuDepartment of Pathology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Chuan XuDepartment of Oncology & Cancer Institute, Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

UrC is a rare malignancy with uncertain pathogenesis. The main symptoms include gross hematuria, abdominal pain, and an abdominal mass. The lack of comprehensive clinical analysis necessitates selecting an optimal therapeutic strategy for each patient. Here, we present a comprehensive review of the clinical manifestations, diagnosis, and treatment of UrC, illustrated with a case successfully managed through surgical intervention and adjuvant chemoradiotherapy. Meanwhile, the analysis of NGS detected two tumor-specific mutated genes: MYC (gene amplification, CN: 59.5) and FLT1 (missense mutation, c.1061G>A (p.R354Q), abundance: 2.1%). These findings may provide insights into tumor growth and guide therapeutic strategies.

Indexed as

chemoradiotherapyFLT1MYCnext-generation sequencingtargeted therapyUrachal carcinoma

Identifiers

PMID42094195
PMCPMC13138954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.